These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18500470)

  • 1. Issues in the treatment of ankylosing spondylitis with non-steroidal anti-inflammatory drugs.
    van der Linden S
    Wien Med Wochenschr; 2008; 158(7-8):195-9. PubMed ID: 18500470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etoricoxib and the treatment of ankylosing spondylitis.
    Lories RJ
    Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1599-608. PubMed ID: 23126318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on nonsteriodal anti-inflammatory drugs.
    Ardoin SP; Sundy JS
    Curr Opin Rheumatol; 2006 May; 18(3):221-6. PubMed ID: 16582683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs.
    Poddubnyy D; Song IH; Sieper J
    Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S148-51. PubMed ID: 19822063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coxibs: a significant therapeutic opportunity.
    Gatti D; Adami S
    Acta Biomed; 2010 Dec; 81(3):217-24. PubMed ID: 22530460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein.
    Benhamou M; Gossec L; Dougados M
    Rheumatology (Oxford); 2010 Mar; 49(3):536-41. PubMed ID: 20028728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [NSAIDs and COX-2-inhibitors: current status].
    Kneitz C; Tony HP; Krüger K
    Internist (Berl); 2006 May; 47(5):533-4, 536-8, 540. PubMed ID: 16557412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COX-2 selective inhibitors in the treatment of osteoarthritis.
    Laine L; White WB; Rostom A; Hochberg M
    Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials.
    Wang R; Dasgupta A; Ward MM
    Ann Rheum Dis; 2016 Jun; 75(6):1152-60. PubMed ID: 26248636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
    Bruno A; Tacconelli S; Patrignani P
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory drugs in the 21st century.
    Rainsford KD
    Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of celecoxib in ankylosing spondylitis treatment.
    Poddubnyy DA; Song IH; Sieper J
    Expert Opin Drug Saf; 2008 Jul; 7(4):401-9. PubMed ID: 18613804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular risk of non-steroidal anti-inflammatory drugs].
    Hermann M
    Praxis (Bern 1994); 2012 Oct; 101(20):1309-14. PubMed ID: 23032496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for the use of cyclooxygenase-2-specific nonsteroidal anti-inflammatory drugs in ankylosing spondylitis: the available evidence.
    Köehler L; Kuipers JG; Zeidler H
    Curr Rheumatol Rep; 2003 Jun; 5(3):178-80. PubMed ID: 12744808
    [No Abstract]   [Full Text] [Related]  

  • 17. Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis.
    Ribaldone DG; Fagoonee S; Astegiano M; De Angelis C; Smedile A; Caviglia GP; Petrini E; Greco A; Pellicano R
    Pain Physician; 2015 Nov; 18(6):599-607. PubMed ID: 26606012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis.
    Baraliakos X; Kiltz U; Peters S; Appel H; Dybowski F; Igelmann M; Kalthoff L; Krause D; Menne HJ; Saracbasi-Zender E; Schmitz-Bortz E; Vigneswaran M; Braun J
    Rheumatology (Oxford); 2017 Jan; 56(1):95-102. PubMed ID: 27997346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.
    Wanders A; Heijde Dv; Landewé R; Béhier JM; Calin A; Olivieri I; Zeidler H; Dougados M
    Arthritis Rheum; 2005 Jun; 52(6):1756-65. PubMed ID: 15934081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular adverse effects of anti-inflammatory drugs.
    Roubille C; Martel-Pelletier J; Davy JM; Haraoui B; Pelletier JP
    Antiinflamm Antiallergy Agents Med Chem; 2013; 12(1):55-67. PubMed ID: 23286294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.